TY - JOUR
T1 - Changes in Serum, Red Blood Cell, and Colonic Fatty Acids in a Personalized Omega-3 Fatty Acid Supplementation Trial
AU - Shen, Yifan
AU - Sen, Ananda
AU - Turgeon, D. Kim
AU - Ren, Jianwei
AU - Graifman, Gillian
AU - Ruffin, Mack T.
AU - Smith, William L.
AU - Brenner, Dean E.
AU - Djuric, Zora
N1 - Funding Information:
The study was supported by the National Cancer Institute (NCI) grant P50 CA130810, the Rogel Cancer Center grant P30 CA046592, the University of Michigan Clinical Research Center grant UL1 RR024986, the Michigan Diabetes Research Center (Chemistry Laboratory) grant P30 DK020572 from the National Institute of Diabetes and Digestive and Kidney Disease, the University of Michigan Rogel Cancer Center Clinical Translational Resource Allocation Committee, the Kutsche Family Memorial Endowment (to DEB), and the Rose and Lawrence C. Page Foundation (to DKT). We thank the individuals who volunteered to participate in this study. Drs. Justin Colacino and Dave Bridges provided helpful discussions, and Kirk Herman was the clinical study coordinator.
Publisher Copyright:
© 2021 Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - This study evaluated changes in fatty acids from sera, red blood cells, and colonic biopsies from a phase Ib clinical trial of personalized ω-3 fatty acid dosing in 47 healthy volunteers. The trial aimed to reduce colonic prostaglandin E2 (PGE2), a pro-inflammatory product of arachidonic acid (AA) oxidation. The personalized doses ranged 2–10 grams/day (54% eicosapentaenoic acid, EPA, 24% other ω-3 fatty acids). In colon, increases in ω-3 highly unsaturated fatty acids (HUFA) and EPA:AA ratios each were correlated with decreases in PGE2. Changes in either colonic EPA:AA ratios or ω-3 HUFA were significantly correlated with changes in the same fatty acid measures in red blood cells or serum. The only blood-based measure significantly correlated with changes in colonic PGE2 was change in red blood cell ω-3 HUFA (ρ = −0.39), and the increase in red blood cell ω-3 HUFA was significantly greater in participants who had at least a median reduction in colonic PGE2 vs. those who did not. In summary, fatty acid changes in blood did reflect fatty acid changes in the colon, but additional factors will be needed for optimizing dosing models that seek to predict the anti-inflammatory effects of ω-3 fatty acids on the colon.
AB - This study evaluated changes in fatty acids from sera, red blood cells, and colonic biopsies from a phase Ib clinical trial of personalized ω-3 fatty acid dosing in 47 healthy volunteers. The trial aimed to reduce colonic prostaglandin E2 (PGE2), a pro-inflammatory product of arachidonic acid (AA) oxidation. The personalized doses ranged 2–10 grams/day (54% eicosapentaenoic acid, EPA, 24% other ω-3 fatty acids). In colon, increases in ω-3 highly unsaturated fatty acids (HUFA) and EPA:AA ratios each were correlated with decreases in PGE2. Changes in either colonic EPA:AA ratios or ω-3 HUFA were significantly correlated with changes in the same fatty acid measures in red blood cells or serum. The only blood-based measure significantly correlated with changes in colonic PGE2 was change in red blood cell ω-3 HUFA (ρ = −0.39), and the increase in red blood cell ω-3 HUFA was significantly greater in participants who had at least a median reduction in colonic PGE2 vs. those who did not. In summary, fatty acid changes in blood did reflect fatty acid changes in the colon, but additional factors will be needed for optimizing dosing models that seek to predict the anti-inflammatory effects of ω-3 fatty acids on the colon.
UR - http://www.scopus.com/inward/record.url?scp=85103047553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103047553&partnerID=8YFLogxK
U2 - 10.1080/01635581.2021.1903950
DO - 10.1080/01635581.2021.1903950
M3 - Article
C2 - 33757398
AN - SCOPUS:85103047553
SN - 0163-5581
VL - 74
SP - 565
EP - 578
JO - Nutrition and cancer
JF - Nutrition and cancer
IS - 2
ER -